Spinal Muscular Atrophy
Pediatric Clinics of North America · 2023-10 · 70 (5) · 963-977
DOI: 10.1016/j.pcl.2023.06.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Clinics of North America, 2023-10. Verfasst von Alex Fay. Beteiligte Einrichtung: University of California, San Francisco, 1875 4th Street., Suite 5A, San Francisco, CA 94158, USA. Electronic address: Alexander.fay@ucsf.edu. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Muscular Atrophy, Spinal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 82 Literaturangaben. Gefördert von: UCSF.
Abstract (Originalsprache)
Spinal muscular atrophy (SMA) is a progressive disease of the lower motor neurons associated with recessive loss of the SMN1 gene, and which leads to worsening weakness and disability, and is fatal in its most severe forms. Over the past six years, three treatments have emerged, two drugs that modify exon splicing and one gene therapy, which have transformed the management of this disease. When treated pre-symptomatically, many children show normal early motor development, and the benefits extend from the newborn period to adulthood. Similar treatment approaches are now under investigation for rare types of SMA associated with genes beyond SMN1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of California, San Francisco, 1875 4th Street., Suite 5A, San Francisco, CA 94158, USA. Electronic address: Alexander.fay@ucsf.edu.
Förderung
- UCSF
Zitieren
APA
Fay, A. (2023). Spinal Muscular Atrophy. Pediatric Clinics of North America, 70(5), 963-977. https://doi.org/10.1016/j.pcl.2023.06.002
Vancouver
Fay A. Spinal Muscular Atrophy. Pediatric Clinics of North America. 2023;70(5):963-977. doi:10.1016/j.pcl.2023.06.002
BibTeX
@article{Fay2023,
author = {Fay, Alex},
title = {Spinal Muscular Atrophy},
journal = {Pediatric Clinics of North America},
year = {2023},
volume = {70},
number = {5},
pages = {963--977},
doi = {10.1016/j.pcl.2023.06.002}
}
EUVIMED